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ABSTRACT 
Introduction: The study aims were to assess the prevalence of good or poor sleep in a 
cohort of axial spondyloarthritis patients and to investigate its correlation with a range of 
objectively and subjectively measured variables in order to develop a model for 
distinguishing good from poor sleepers . 
Methods: Five hundred ninety-eight patients with ankylosing spondylitis and 61 with 
nonradiographic axial spondyloarthritis completed the Jenkins Sleep Evaluation 
Questionnaire. Measures of disease activity, mobility, function, mood, fatigue, quality of life, 
work productivity, night-time pain and general health were gathered. 
Results: Patients with ankylosing spondylitis or nonradiographic axial spondyloarthritis were 
initially compared. With the exception of waking up tired less often and having lower 
mobility and functioning, the two groups were similar so were combined for subsequent 
analysis. Twenty-nine percent of all patients were classified as good sleepers and 19% as 
poor sleepers. Poor sleepers had higher disease activity and fatigue scores and more night-
time back pain than good sleepers. They reported poorer quality of life, general health, 
mood, and work-related measures. A model incorporating mood, gender, fatigue and 
objective and subjective judgements of disease activity correctly classified 87.3% of good 
and poor sleepers. 
Conclusions: Poor sleep was strongly associated with poor mood, female gender, greater 
fatigue, greater disease activity (specifically, spinal pain and stiffness) and better mobility, 
however, the direction of causality between poor sleep and markers of active disease was 
undetermined. This study also highlights the need to standardise the measurement of sleep 
disturbance in axSpA to facilitate comparisons between patient groups and interventions. 
KEYWORDS: 
Ankylosing Spondylitis, Sleep, Fatigue, Gender, Quality of Life  
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INTRODUCTION  
Axial Spondyloarthritis (axSpA) including ankylosing spondylitis (AS) and non-radiographic 
axial spondyloarthritis (nr-axSpA) are chronic inflammatory conditions which mainly affect 
the spine. The pain and stiffness associated with them are strongly implicated in poor sleep 
which, itself, has been identified as a major quality of life (QoL) concern for patients [1, 2] and 
contributor to work impairment and work hours lost [3]. Sleep disturbance has been 
reported in up to 80% of AS patients [4] yet the focus of published research in this area varies 
considerably. Sleep has been the primary outcome in a small number of studies [4, 5, 6], but is 
more often analysed as a secondary outcome [7, 8, 9]. This paper concerns variables that 
distinguish good from poor sleepers as its main focus and is the first of its kind to be based 
on a large, UK patient sample. 
Outcome measures used to assess sleep in these studies include the Pittsburgh Sleep 
Quality Index (PSQI) [10], the Medical Outcomes Study sleep questionnaire (MOS) [11], the 
Jenkins Sleep Evaluation Questionnaire (JSEQ) [12] and the Uppsala Sleep Inventory (USI) [13]. 
The majority of studies involve subjective, self-report measures, but some include objective 
measures such as polysomnography [14]. Higher scores on the Bath Ankylosing Spondylitis 
and Functioning Indexes (BASDAI and BASFI), for disease activity and daily functioning 
respectively, are frequently associated with poorer sleep in such studies. Comorbid 
conditions, such as inflammatory bowel disease [15, 16], have also been measured and 
implicated in poor sleep in AS patients, as have anxiety and depression [17]. 
Age is a key variable with regard to sleep patterns in AS and the effects found are mixed. 
However, reliable associations between age and sleep are difficult to establish even in 
healthy populations [18], and are further complicated by inherent and circumstantial 
individual differences in sleep needs, patterns and preferences [19].  
A further key variable is gender. Two studies [1, 2] showed that men and women with AS 
equally rate sleep improvement as a priority but did not show whether or how their actual 
sleep patterns differed. A further study of 70 Swedish AS patients showed that sleep 
disturbance was more prevalent amongst females: insufficient sleep was reported by 80.8% 
of females compared to 50.0% of males. In addition, more females reported significantly 
more difficulty with falling and staying asleep, pain at bedtime, and in the night, and fatigue 
[4]. 
Some studies concern the efficacy of interventions to improve sleep. These include exercise 
[20] or use of non-steroidal anti-inflammatory medication [3, 7, 21, 22, 23]. Anti-tumour necrosis 
factor (Anti-TNF) therapies, when assessed as a secondary outcome in large phase 3 studies, 
have been shown to improve sleep in longitudinal studies [3, 21, 22, 23].  
The main aim in this study was to assess the extent to which variables identified in the 
aforementioned research literature could distinguish between axSpA patients who 
experience good or poor sleep. To achieve this, the demographic variables of age, gender 
and disease duration were recorded along with Bath Ankylosing Spondylitis measures of 
disease activity (BASDAI) [24], functioning (BASFI) [25] and metrology (BASMI) [26]. A secondary 
aim was to analyse total and sub-scale scores, as well as to take separate measures which 
tend to be duplicated within scales such as fatigue and back pain, in order to check their 
correspondence with each other. Other measures of comorbidities, mood 
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(anxiety/depression), QoL, medication use, general health and functioning at work were also 
taken. These variables were compared in relation to disease (nr-axSpA and AS) and 
good/poor sleep classification. Key variables thus identified were then combined to assess 
their unique contribution to distinguishing good or poor sleep.  
MATERIALS AND METHODS 
Patients. This is a cross-sectional, observational, single-centre study in UK patients with 
axSpA, which commenced in July 2010 and has been ongoing up to the present. AxSpA 
patients were classified according to the ASAS axSpA criteria. Patients subsequently also 
meeting modified New York Criteria were classified as having AS whilst all other patients 
were deemed to have nr-axSpA. Data have been collected over a 5-year period from 
patients attending the Royal National Hospital for Rheumatic Diseases (RNHRD), Bath, under 
the care of a single rheumatologist (RS). Although data were collected at each visit, for each 
patient over this 5-year period, the focus of the current analyses is on the latest patient-
reported information on sleep status and related factors. The latest time point used for 
cross-sectional analysis fell between September 2013 and June 2015. Bristol UK local 
research ethics committee (LREC) for National Health Service research approved the study, 
and all patients provided informed, written consent. (The Bath Spondyloarthritis (SpA) 
Biobank; REC reference: 13/SW/0096.) 
 
Measures. The sleep measure used was the Jenkins Sleep Evaluation Questionnaire (JSEQ) 
which has an internal consistency of alpha = .79 [12]. It consists of four items asking about 
trouble falling asleep, waking several times in the night, trouble staying asleep and waking 
up feeling tired and worn out. Patients respond on a six-point scale indicating frequency of 
these problems during the past month and can score between 4 and 24. Low JSEQ (good 
sleep) was defined as problems on 3 days or fewer (≤ 8 points) and high JSEQ (poor sleep) as 
problems on 15 days or more (≥ 20 points) in the past month. In the absence of normative 
data for the patient group, this division was decided upon because it clearly distinguished 
patients whose sleep was hardly ever disturbed from those who experienced sleep 
problems on at least 50% of nights. 
Disease characteristics were measured using the BASDAI, BASFI and BASMI. Fatigue was 
measured using the Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale 
V4.0 [27] and quality of life using the Ankylosing Spondylitis Quality of Life questionnaire 
(ASQoL) [28]. Back pain (night) and back pain (any time) measures were taken on a 0 none - 
10 most severe visual analogue scale (VAS). The presence of extra articular manifestations 
(EAMs) of axSpA (IBD, uveitis and psoriasis) were recorded. 
Mood and general health state were measured using the EuroQol five dimensions 
questionnaire (EQ5D) [29] Anxiety/Depression item (none, moderate, extreme) and general 
health state VAS (0 worst imaginable - 100 best imaginable). 
For patients in work, two questions from the Work Productivity and Activity Impairment 
Questionnaire Specific Health Problem (WPAI:SHP V1.0) were used [30]: Q2 (work hours 
missed) and Q5 (productivity at work VAS: 0 no effect – 10 completely prevented from 
working) in the past 7 days. 
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Statistical analysis. IBM Statistical Package for the Social Sciences version 22 (IBM SPSS v.22) 
was used for all analyses. Kolmogorov-Smirnov tests revealed non-normal distributions in 
continuous data samples so medians, interquartile ranges (IQR) and percentages were used 
as descriptive statistics. Non-parametric, two-tailed, Mann Whitney U tests were used on 
continuous scale data to detect differences between AS and nr-axSpA patients, and good 
and poor sleepers. Chi square analyses were used to test for associations in frequency data. 
Direct binary logistic regression was used to test for the independent contribution of factors 
likely to predict good or poor sleep group membership. These factors, specifically gender, 
mood and individual BASDAI scale items, were chosen because of their likely impact upon 
night-time sleep rather than daytime functioning and their statistical significance in 
preceding tests. Although BASMI was non-significant at that point it was incorporated into 
the final model because it is a more objective test of functioning and its effect might be 
moderated by other co-variables. Collinearity statistics indicated that none of these 
predictor variables were problematic: Tolerance ≥ .20, VIF (Variance Inflation Factor) ≤ 5.22. 
p ≤. 05 wer applied to all statistical tests. 
RESULTS 
Patient demographics, disease characteristics and comorbidity. There were 659 patients in 
total, aged 18-84 years (median = 51, IQR = 41-61 years) at the time of testing and 24% were 
female. Table 1 contains summary statistics for all patients and by diagnostic group. Ninety-
one percent were AS patients. As would be expected due to stage of disease, they were 
significantly older (median 53, IQR = 42-63 years) than nr-axSpA patients (median 37, IQR = 
28-44 years) and reported more years since diagnosis (median = 20, IQR = 9-31 v. median = 
3, IQR = 2-8.75 years) and since symptom onset (median = 30, IQR = 20-41 v. median = 9.50, 
IQR = 5-19 years). Diagnostic groups did not differ in age at diagnosis, symptom onset or 
delay in diagnosis (p ≥ .11). Comorbid IBD and psoriasis were not associated with diagnostic 
group but uveitis was, rising from 27.9% in nr-axSpA to 42.8% in AS. 
Frequency of patients with low, medium and high JSEQ scores. Low JSEQ scores indicate 
problems on three days or fewer, medium scores on 4-14 days and high scores on 15 days 
or more in the past month. For each JSEQ item, the approximate percentages of patients 
falling into each low : medium : high category were: ‘trouble falling asleep’, 61.0 : 20.1 : 
18.9; ‘waking several times in the night’, 33.8 : 26.7 : 39.5;  ‘trouble staying asleep’, 40.5 : 
27.0 : 32.5;  ‘wake up feeling tired and worn out’, 36.8 : 27.5 : 35.7. 
Comparisons by diagnostic (AS and nr-AxSpA) group. In Table 1, BASDAI and JSEQ scores 
indicated that AS patients, when compared to nr-AxSpA patients, experienced less stiffness 
duration and upon waking (p ≤ .03), were less likely to wake up tired (p = .02). AS patients 
had higher BASMI (spinal movement changes) scores (p = .00001) and BASFI scores (p = 
.002) than nr-axSpA patients. Table 1 otherwise indicates little difference between AS and 
nr-axSpA patients in BASDAI and JSEQ scores. For this reason, patients are grouped together 
for further analyses. 
INSERT Table 1: Comparison of patients with AS or nr-axSpA.  
Comparisons of good and poor sleepers. Table 2 contains data comparing good sleepers (low 
JSEQ, n = 173) and poor sleepers (high JSEQ, n = 112). Good and poor sleepers comprise 29% 
and 19% of all patients respectively. AS and nr-axSpA patients are combined due to 
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negligible differences in JSEQ evident in Table 1. Gender and sleep group were associated 
such that men predominated in the good sleep group (80.9%) but less so (64.2%) in the poor 
sleep group (p < .003). All BASDAI scales, BASFI, ASQoL, back pain and EQ5D: General health 
state comparisons indicated significantly worse outcomes for poor sleepers compared to 
good sleepers (p < .00001). EQ5D: Anxiety/Depression was lower (p <.00001) in good 
sleepers (21.2%) compared to in poor sleepers (65.5%). Amongst patients who worked, poor 
sleepers reported more work hours missed and poorer productivity at work (p ≤ .007) than 
good sleepers.  
None of the variables relating to age, diagnosis time or symptom onset differed between 
JSEQ groups. There were no differences in BASMI scores or frequency of co-morbid 
conditions (p ≥ .27). 
INSERT Table 2:  Comparison of patients with high and low Jenkins Sleep Evaluation 
Questionnaire (JSEQ) scores. 
Unique predictors of good or poor sleep. Direct logistic regression was performed to assess 
the unique impact of nine independent variables (gender, BASMI, six BASDAI sub-scales and 
mood) on the likelihood that patients would report poor sleep (high JSEQ) scores. The 
BASMI was chosen as an objective measure of functioning and the others because of their 
relevance to night-time sleep and immediately after waking. Other measures that differed 
between sleep groups (BASFI and WPAI:SHP items) were excluded because they measure 
daytime functioning. ASQoL, FACIT and EQ5D: general health were excluded because of 
some overlap with items in other scales. High correlations between BASDAI spinal pain and 
back pain VAS measures (rho (630) = .71 to .74, p < .00001, two tailed) and between BASDAI 
fatigue and FACIT (rho (697) = .69, p < .00001, two tailed) justified use of the BASDAI 
measures only. 
The full model, containing all the predictors and shown in Table 3, was statistically 
significant, ² (8, N = 272) = 206.41 p <.00001, indicating that it could be used to distinguish 
between patients who reported sleep disruption on three days or fewer compared to 15 or 
more days in the past month. The model as a whole explained between 54.8% (Cox and 
Snell R Square) and 74.0% (Nagelkerke R Square) of the variance in sleep status and 
correctly classified 87.3% of cases. Table 3 shows that seven of the nine independent 
variables made a unique and statistically significant contribution to the model. The strongest 
predictor was EQ5D: Anxiety/Depression. The odds ratio indicated that for patients who 
assessed themselves as moderately to extremely anxious and depressed, high JSEQ 
classification was 7.18 times more probable than for those did not feel anxious and 
depressed. High JSEQ classification was 3.13 times more probable for females than for 
males. The odds ratio for BASDAI fatigue indicated that for every additional scale point, high 
JSEQ classification was 2.17 times more probable than low JSEQ classification. The odds 
ratio for BASDAI stiffness duration after waking indicated that for every additional scale 
point, high JSEQ classification was 1.99 times more probable than low JSEQ classification. 
The odds ratio for BASDAI spinal pain indicated that for every additional scale point, high 
JSEQ classification was 1.58 times more probable than low JSEQ classification. Finally, two 
predictors had weak, negative relationships with sleep category. The odds ratios for BASMI 
were 0.73 and for BASDAI stiffness on waking were 0.59. Taking the inverse of these, for the 
sake of clarity, they indicate that for every additional BASMI scale point, low JSEQ 
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classification was 1.38 times more probable than high JSEQ classification and for every 
additional BASDAI stiffness scale point, low JSEQ classification was 1.70 times more 
probable than high classification.  
INSERT Table 3: Logistic regression predicting the likelihood of high Jenkins Sleep Evaluation 
Questionnaire (JSEQ) scores. 
DISCUSSION 
This study is, to our knowledge, the largest study of sleep disturbance in AS (or axial SpA) 
patients in the UK. Poor sleepers reported greater disease activity on all BASDAI measures, 
greater fatigue, poorer daily functioning, more back pain, reduced quality of life, poorer 
general health and greater incidence of EQ5D: Anxiety/Depression when compared to good 
sleepers. For those in work, poor sleepers missed more work hours and felt less productive. 
These differences appear not to be confounded by age, bearing in mind that, while sleep 
requirements change with age, the subjective sensation of poor or good sleep does not, at 
least among these patients. In addition, years since diagnosis and symptom onset and 
comorbid conditions (IBD, uveitis and psoriasis) are not implicated.  
Further testing for the unique contribution of key variables to predicting poor or good sleep 
group classification was carried out. Together, these variables correctly classified 87.3% of 
patients. The order of ORs, starting with the highest, was EQ5D: Anxiety/Depression, female 
gender, BASDAI fatigue, stiffness duration, spinal pain, BASMI and stiffness on waking. 
Higher BASDAI stiffness on waking and BASMI predicted low JSEQ classification (less 
disturbance) while higher scores on the other 5 variables predicted high JSEQ classification 
(more disturbance). Effect size benchmarks [31] indicate a large effect for EQ5D: 
Anxiety/Depression, medium effects for gender and BASDAI fatigue and small effects for 
BASMI and BASDAI stiffness duration, stiffness on waking and spinal pain. 
With regard to mood, we have shown that, for axSpA patients who report moderate to 
severe anxiety and depression, high JSEQ classification was 7.18 times more probable than 
for those did not feel anxious and depressed. Other studies attempting to link mood 
problems with sleep patterns in AS, but measuring depression alone, have produced 
equivocal results Two recent studies have linked greater depression with poorer sleep 
quality [6, 17] and two have not [4, 14]. Discrepancies may be partly due to the measures used, 
for example, whether they were standardised on clinical groups or not or comprised a single 
question, as well as the presence of other interacting but uncontrolled variables such as 
gender and age. The single, composite anxiety/depression question used here asked about 
two different, although arguably related, aspects of mood.  Nevertheless, it was the 
strongest predictor of sleep group in this study and so deserves further scrutiny, ideally 
using more sensitive measures which distinguish anxiety and depression. 
The second most important predictor of sleep group was gender which accords with one 
other study focusing on this [4]. The current study showed that females comprised 19.1% of 
the good sleep group as compared to 35.7% of the poor sleep group. For females in our 
cohort, high JSEQ classification was 3.13 times more probable than it was for males. These 
figures must be taken in the context of a predominantly male patient group. Age and stage 
of disease are additional confounders. In one meta-analysis to establish norms for healthy 
individuals across the lifespan [18], it was concluded that stage I and II sleep increased and 
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REM sleep decreased with age. Changes were greater for women, although in a similar 
direction to those in men, and patterns changed when ill-health-related variables were 
included. In this study, Table 2 shows no differences in age-related variables between sleep 
groups, suggesting that subjective sleep disturbance remains more prevalent amongst 
females regardless of age and stage of disease. However, middle-aged individuals, who 
make up most of the current patient group, were not well-represented in the 
aforementioned meta-analysis, rendering meaningful comparisons difficult.   
Findings linking higher BASDAI scores with poorer sleep are robust [4, 5, 6, 9, 14, 17] and in 
agreement with the current study, where it is shown that fatigue, spinal pain and stiffness 
are unique predictors of poor sleep. As an objective measure of disease activity, BASMI also 
made a significant contribution. The causal direction of all these effects however is 
undetermined.  
On a note of caution, in the original JSEQ development paper, the items mean = 2.38* in a 
non-clinical group (n = 250) [12]. (*Figure adjusted to correspond to our 4-24 scale. The 
original paper used 0-20.) This is lower than for all patients in this study: mean (SD) = 3.31 
(1.48), t (643) = 16.00, p < .0001, two-tailed). It is also much lower than the poor sleep group: 
mean (SD) = 5.60 (0.39), t = 87.51 (111), p < .00001, two-tailed, and higher than the good 
sleep group: mean (SD) = 1.54 (0.35), t (172) = -31.82, p < .00001), two-tailed, in this study. 
However, the original study utilised only working males whose average age was limited to 
25 to 49 years. These factors, and the presence of skewed data samples in the current 
study, make meaningful comparisons with the current patients difficult, nevertheless the 
clear distinction between good and poor sleepers in this study lends validity to the 
conclusions drawn. 
Studies of sleep such as this one, in naturalistic settings and based on self-report, are 
inherently difficult to control. However, highly controlled, laboratory-based, 
polysomnography research may not adequately reflect everyday sleeping conditions. Sleep 
in domestic settings is likely to be social [32] and, therefore, vulnerable to disturbance by 
others [33]. Few studies record these things, with one exception - a Turkish study in which it 
was reported that 81.1% of n=55 had a co-sleeper [5]. Secondly, sleep is often affected by 
uncontrollable external influences [34]. Finally, there are individual differences in sleep 
patterns and preferences [19] which are rarely taken into account in any kind of study [33].  
CONCLUSIONS  
In conclusion, findings in this study suggest a strong link between poor sleep and mood, 
gender, disease activity and mobility in AS and nr-axSpA patients. This study is the first of its 
kind based in the UK. The varied locations of other studies (Egypt [14], Turkey [5, 6] and China [9, 
17]) lend contextual and population validity to the findings. This study further highlights the 
need to standardise the measurement of sleep disturbance in axSpA to allow future 
comparisons between patient groups and interventions. 
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Table 1 
Comparison of patients with AS or nr-axSpA. BASDAI stiffness scores are the mean of items 5 
(stiffness on waking) and 6 (duration of stiffness). Scale values are medians (interquartile range) and 
frequency data are % unless otherwise stated. 
Variables Total n = 659  nr-AxSpA n = 61  AS n = 598 p 
% Male 76 59 78 .002 
Age (yrs) 51 (41-61) 37 (28-44) 53 (42-63) <.00001 
Years since diagnosis 19 (8-30) 3 (2-8.75) 20 (9-31) <.00001 
Age at diagnosis (yrs) 29 (23-37) 31 (25-35.50) 28 (23-37) .60 
Age at symptom onset (yrs) 21 (17-26) 23 (16.25-29) 21 (17-26) .28 
Years since symptom onset 28 (18-40) 9.50 (5-19) 30 (20-41) <.00001 
Delay in diagnosis (yrs) 6 (2.25-12.00) 4 (2-11) 6 (3-12) .11 
% Inflammatory bowel 
disease present 
8.0 1.6 8.7 .09 
% Uveitis present 41.4 27.9 42.8 .03 
% Psoriasis present 16.2 8.2 17.1 .11 
BASDAI Total (All scales 0-
10) 
3.67 (2.17-5.33) 4.17 (2.83-6.00) 3.67 (2.17-5.17) .11 
- BASDAI fatigue 5.00 (3.00-7.00) 5.00 (3.00-7.00) 5.00 (3.00-7.00) .51 
- BASDAI spinal pain 4.00 (2.00-7.00) 6.00 (3.00-7.00) 4.00 (2.00-7.00) .09 
- BASDAI arthralgia 3.00 (1.00-5.00) 3.00 (1.00-5.00) 3.00 (1.00-5.00) .95 
- BASDAI enthesitis 3.00 (1.00-6.00) 3.00 (1.00-6.00) 3.00 (1.00-6.00) .74 
- BASDAI stiffness 3.00 (1.50-5.00) 4.00 (2.00-6.00) 3.00 (1.50-5.00) .02 
- on waking 4.00 (2.00-6.00) 4.50 (3.00-7.00) 3.00 (2.00-6.00) .02 
- duration 3.00 (1.00-4.00) 3.00 (1.00-5.00) 2.00 (1.00-4.00) .03 
JSEQ Total (All scales 1-6) 3.25 (2.00-4.50) 3.12 (2.25-4.34) 3.25 (2.00-4.50) .66 
- JSEQ falling asleep 2.00 (1.00-4.00) 2.00 (1.00-4.00) 2.00 (1.00-4.00) .93 
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- JSEQ wake several 
times 
4.00 (2.00-6.00) 4.00 (2.00-5.00) 4.00 (2.00-6.00) .61 
- JSEQ staying asleep 3.00 (2.00-5.00) 3.00 (2.00-5.00) 3.00 (2.00-5.00) .44 
- JSEQ wake up tired 3.00 (2.00-5.00) 5.00 (2.00-6.00) 3.00 (2.00-5.00) .02 
FACIT (0-42) 20.00 (12.00-30.00) 20.00 (12.00-
32.00) 
20.00 (12.00-
29.50) 
.82 
BASMI (0-10) † 3.00 (1.60-5.20) 1.00 (0.40-1.60) 3.20 (1.80-5.40) <.00001 
BASFI (1 easy-100 
impossible) 
36.00 (17.00-58.00) 21.00 (10.00-
47.00) 
37.00 (18.00-
59.00) 
.002 
ASQoL (0-36) 6.00 (2.00-11.00) 5.00 (2.75-12.00) 7.00 (2.00-11.00) .81 
Back pain (night 0-10) 3.00 (1.00-5.00) 3.00 (2.00-6.00) 3.00 (1.00-5.00) .38 
Back pain (any time 0-10) 3.00 (2.00-6.00) 4.00 (2.00-7.00) 3.00 (2.00-6.00) .02 
WPAI:SHP V1.0 Q2 (Work 
hours missed in the past 7 
days.) †† 
0.00 (0.00-0.00) 0.00 (0.00-0.00) 0.00 (0.00-0.00) .38 
WPAI:SHP V1.0 Q5 (Work 
productivity, 0 no effect – 
10 could not work.) ††† 
2.00 (0.00-4.00) 2.00 (1.00-4.00) 2.00 (0.00-4.00) .57 
EQ5D: General health state 
(0 worst-100 best 
imaginable.) 
66.00 (50.00-80.00) 71.00 (50.00-
80.00) 
65.00 (50.00-
80.00) 
.11 
% EQ5D: Anxiety 
Depression: moderate-
extreme 
41 34.5 41.5 .37 
Note: BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; JSEQ: Jenkins Sleep Evaluation 
Questionnaire; FACIT: Functional Assessment of Chronic Illness Therapy; BASFI: Bath Ankylosing Spondylitis 
Functional Index; BASMI: Bath Ankylosing Spondylitis Metrology Index; ASQoL: Ankylosing Spondylitis Quality 
of Life; WPAI:SHP: Work Productivity and Activity Impairment Questionnaire: Specific Health Problem; EQ5D: 
EuroQol 5 dimension health status questionnaire. † n = 284 (nr-axSpA n = 262, AS n = 22). †† n = 350 (nr-axSpA 
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n = 45, AS n = 305). ††† n = 372 (nr-axSpA n = 45, AS n = 327). p (two tailed) values refer to Mann-Whitney 
tests for AS vs nr-axSpA or chi square for frequency comparisons of two-level categorical variables (gender: 
male, female; % inflammatory bowel disease, uveitis, psoriasis: present or not; EQ5D Anxiety depression: 
none, moderate-extreme) with JSEQ low/high categories. There were small variations in other sample sizes 
due to incomplete data. 
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Table 2 
Comparison of patients with high and low Jenkins Sleep Evaluation Questionnaire (JSEQ) scores. Low 
JSEQ indicates problems on three days or fewer and high JSE on 15 days or more in the past month. 
BASDAI stiffness scores combine items 5 (stiffness on waking) and 6 (duration of stiffness). Scale 
values are medians (interquartile range) and frequency data are % unless otherwise stated. 
Variables Total n = 285 Low JSEQ n = 173 High JSEQ n = 112 p 
% Male 74.4 80.9 64.3 .003 
Diagnosis AS/nr-AxSpA 92.3/7.7 93.1/6.9 91.1/8.9 .70 
Age (yrs) 50 (39-61) 49 (37.5-61.5) 52 (41-61) .74 
Years since diagnosis 16 (8-28) 16 (7-27) 17 (8-29) .57 
Age at diagnosis (yrs) 28 (23-38) 27.50 (23-38) 30.00 (23-38) .87 
Age at symptom onset 
(yrs) 
21 (17-26.25) 21 (17-26) 25 (15-38) .44 
Years since symptom 
onset 
25.50 (15.75-38) 20 (17-27) 26 (16-38.5) .80 
Delay in diagnosis (yrs) 6 (2-12) 5 (2-11) 7 (2.75-13) .27 
% Inflammatory bowel 
disease present 
5.6 5.8 5.4 1.00 
% Uveitis present 40.0 38.2 42.9 .50 
% Psoriasis present 15.1 14.5 16.1 .84 
BASDAI Total (All scales: 
0-10) 
3.50 (1.83-5.66) 2.50 (1.33-3.66) 5.50 (4.00-6.83) <.0001 
- BASDAI fatigue 5.00 (2.00-7.00) 3.00 (2.00-5.00) 7.00 (5.00-8.00) <.0001 
- BASDAI spinal pain 5.00 (2.00-7.00) 3.00 (2.00-5.00) 7.00 (5.00-8.00) <.0001 
- BASDAI arthralgia 3.00 (1.00-5.00) 2.00 (0.00-4.00) 5.00 (2.00-7.00) <.0001 
- BASDAI enthesitis 3.00 (1.00-6.00) 2.00 (0.00-4.00) 5.00 (2.00-7.00) <.0001 
- BASDAI stiffness 3.00 (1.50-5.50) 2.00 (1.00-3.50) 5.00 (3.00-7.00) <.0001 
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- on waking 3.00 (2.00-6.00) 2.00 (1.00-4.00) 5.00 (3.00-8.00)  <.0001 
- duration 2.00 (1.00-4.00) 2.00 (1.00-3.00) 4.00 (2.00-6.00) <.0001 
FACIT (0-42) 17.00 (9.00-29.00) 11.50 (8.00-17.25) 30.00 (23.00-38.00) <.0001 
BASMI (0-10) † 3.00 (1.60-5.20) 3.00 (1.40-5.20) 2.70 (1.60-5.30) .70 
BASFI (1 easy - 100 
impossible) 
32.00 (15.00-57.25) 23.50 (10.00-41.00) 56.00 (32.50-76.00) <.0001 
ASQoL (0-36) 5.00 (1.00-11.00) 2.00 (0.00-6.00) 11.00 (8.00-15.00) <.0001 
Back pain (night 0-10) 3.00 (1.00-6.00) 2.00 (1.00-3.00) 6.00 (3.00-8.00) <.0001 
Back pain (any time 0-10) 3.00 (1.00-6.00) 2.00 (1.00-3.00) 6.00 (3.00-8.00) <.0001 
WPAI:SHP V1.0 Q2 (Work 
hours missed in the past 7 
days.) †† 
2.38 (0.00-0.00) 0.00 (0.00-0.00) 3.64 (0.00-2.25) .007 
WPAI:SHP V1.0 (Work 
productivity Q5, 0 no 
effect – 10 could not 
work.) ††† 
2.00 (0.00-4.00) 1.00 (0.00-2.00) 4.00 (2.00-6.00) <.0001 
EQ5D: General health 
state (0 worst-100 best 
imaginable.) 
69.00 (50.00-80.00) 73.00 (57.75-85.00) 50.00 (39.75-70.00) <.0001 
% EQ5D: Anxiety 
Depression: moderate-
extreme 
38.6 21.2 65.5 <.0001 
Note: BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; FACIT: Functional Assessment of Chronic 
Illness Therapy; BASFI: Bath Ankylosing Spondylitis Functional Index; BASMI: Bath Ankylosing Spondylitis 
Metrology Index; ASQoL: Ankylosing Spondylitis Quality of Life; WPAI:SHP: Work Productivity and Activity 
Impairment Questionnaire: Specific Health Problem; EQ5D: EuroQol 5 dimension health status questionnaire† 
n = 205 (Low JESQ n = 133, High JESQ n = 72). †† n = 150 (Low JESQ n = 100, High JESQ n = 50). ††† n = 150 
(Low JESQ n = 102, High JESQ n = 48). p (two tailed) values refer to Mann-Whitney tests for high vs low JSEQ or 
chi square for frequency comparisons of two-level categorical variables (gender: male, female; inflammatory 
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bowel disease, uveitis, psoriasis: present or not; EQ5D Anxiety depression: none, moderate-extreme) with 
JSEQ low/high categories. There were small variations in other sample sizes due to incomplete data. 
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Table 3 
Logistic regression predicting the likelihood of high Jenkins Sleep Evaluation Questionnaire (JSEQ) 
scores. Low JSEQ indicates problems on three days or fewer and high JSEQ on 15 days or more in the 
past month. 
Variables B Standard Error OR 95% CI p 
Gender  1.20 0.51 3.13 1.16-8.43 .02 
BASMI -0.32 0.11 0.73 0.58-0.91 .005 
BASDAI fatigue  0.78 0.14 2.17 1.64-2.87 <.00001 
BASDAI spinal pain  0.46 0.14 1.58 1.19-2.09 .001 
BASDAI arthralgia  0.07 0.11 1.08 0.88-1.32 .49 
BASDAI enthesitis -0.04 0.13 0.96 0.75-1.23 .77 
BASDAI stiffness on waking -0.54 0.19 0.59 0.40-0.85 .005 
BASDAI stiffness duration  0.69 0.18 1.99 1.40-2.83 .0001 
EQ5D: Anxiety Depression: 
none/moderate-extreme 
 1.97 0.48 7.18 2.81-18.33 .00004 
Note: BASMI: Bath Ankylosing Spondylitis Metrology Index; BASDAI: Bath Ankylosing Spondylitis Disease 
Activity Index; EQ5D: EuroQol 5 dimension health status questionnaire. N = 272. 
 
 
 
 
 
